股票行情快报：蓝帆医疗（002382）11月3日主力资金净卖出237.52万元

Core Viewpoint - Bluefan Medical (002382) has shown a slight increase in stock price but continues to face significant financial challenges, with declining revenues and profits in recent quarters [1][3]. Financial Performance - As of November 3, 2025, Bluefan Medical's stock closed at 5.51 yuan, up 0.18% with a trading volume of 74,000 shares and a turnover of 40.68 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 14.01 billion yuan, a year-on-year decrease of 15.02%, and a net profit attributable to shareholders of -1.51 billion yuan, a decline of 153.64% [3]. - For the first three quarters of 2025, the total revenue was 41.82 billion yuan, down 10.15%, with a net profit of -2.86 billion yuan, a decrease of 30.09% [3]. Market Position - Bluefan Medical's total market capitalization is 5.549 billion yuan, ranking 64th in the medical device industry, which has an average market cap of 11.617 billion yuan [3]. - The company's net asset value stands at 9.707 billion yuan, significantly higher than the industry average of 3.893 billion yuan, ranking 7th [3]. - The company has a price-to-earnings ratio of -14.55, while the industry average is 63.42, indicating a challenging profitability outlook [3]. Profitability Metrics - Bluefan Medical's gross margin is 13.66%, compared to the industry average of 51.22%, ranking 121st in the industry [3]. - The net profit margin is -7.24%, significantly lower than the industry average of 9.57%, ranking 109th [3]. - The return on equity (ROE) is -3.56%, while the industry average is 0.15%, indicating poor financial performance relative to peers [3]. Capital Flow Analysis - On November 3, 2025, the net outflow of main funds was 2.3752 million yuan, accounting for 5.84% of the total turnover, while retail investors saw a net inflow of 1.4859 million yuan, representing 3.65% of the total turnover [1][2]. - Over the past five days, the stock has experienced fluctuating capital flows, with significant net outflows from main funds on several days, indicating a lack of confidence from institutional investors [2].